Diabetes Savings Offer Program

Novo Nordisk Savings Offer

Eligibility and Restrictions:

In order to redeem this offer, patient must have a valid prescription for the brand being filled. A valid Prescriber ID# is required on the prescription. Patient is not eligible if he/she is enrolled in any federal or state health care program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in a commercial insurance plan. The brand and the prescription being filled must be covered by the patient’s commercial insurance plan. Offer excludes full cash-paying patients. This offer may not be redeemed for cash. This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by a commercial insurance plan or other commercial health or pharmacy benefit programs. By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described herein and will not seek reimbursement for any benefit received through this offer. Novo Nordisk’s Eligibility and Restrictions, and Offer Details may change from time to time, and for the most recent version, please visit this webpage. Re-confirmation of patient information may be requested periodically to ensure accuracy of data and compliance with terms. Patients with questions about the Savings Offer may call 1-877-304-6855.

This offer is valid only in the United States and its territories, unless prohibited by law, and may be redeemed at participating retail pharmacies. Availability of the Savings Offer in Massachusetts will be dependent upon state law in effect at the time patient presents the Savings Offer when paying for the covered medications. 

This offer is not transferable and is limited to one offer per person. Not valid if reproduced.

Cash Discount Cards and other non-insurance plans are not valid as primary insurance under this offer. If the patient is eligible for drug benefits under any such program, the patient cannot use this offer. This Savings Offer cannot be combined with any coupon, certificate, voucher, or similar offer. No other purchase is necessary.

Patient is responsible for complying with any insurance carrier copayment disclosure requirements, including disclosing any savings received from this program. Novo Nordisk intends that all savings from this offer accrues to the patient. It is illegal to (or offer to) sell, purchase, or trade this offer.

This program is not health insurance. This program is managed by ConnectiveRx on behalf of Novo Nordisk. The parties reserve the right to rescind, revoke, or amend this offer without notice at any time.

Offer Details:

This offer is good for eligible patients purchasing up to a 90-day supply.

(a)  FIASP® (insulin aspart) injection 100 U/mL: If you enrolled and redeemed your offer on, or prior to 08/07/2023 you may pay as little as (“PALA”) $25 per 30-day, $50 per 60-day, or $75 per 90-day supply for up to 24 months from the date of Savings Offer activation or until offer expiration subject to a maximum savings of $150 per 30-day, $300 per 60-day, or $450 per 90-day supply. Offer expires December 31, 2023. To enroll after 08/07/2023 or upon this Savings Offer expiration, please visit Novocare.com.

(b) OZEMPIC® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg: Pay as little as (“PALA”) $25, subject to a maximum savings of $150 per 1-month prescription, $300 per 2-month prescription, $450 per 3-month prescription, for up to 24 months from the date of Savings Offer activation. Month is defined as 28 days. In order to obtain the “PALA $25 per 3-month prescription” offer, the patient must have a prescription for a 3-month supply, and the patient’s commercial insurance plan must provide coverage for a 3-month fill.

(c) RYBELSUS® (semaglutide) tablets 7 mg or 14 mg:

  • If you enrolled for your offer on, or prior to, January 31, 2020, and have a group number of EC20024001 or EC20024003:
    • Pay $10 for up to twelve, 30-day fills of RYBELSUS® through May 31, 2021. After the patient’s twelfth fill, or on June 1, 2021, whichever comes first (the “transition date”), patients without coverage on their commercial plan are no longer eligible for this Program. Those patients who have commercial insurance for RYBELSUS® at the time of the transition date will then pay as little as (“PALA”) $10 per 30-day supply, $10 per 60-day supply, or $10 per 90-day supply for up to 24 months from the activation date, subject to a maximum savings of $300 per a 30-day supply, $600 per 60-day supply, or $900 per 90-day supply. RYBELSUS® 3 mg strength is limited to a 30-day supply only.
  • If you enrolled for your offer on, or after, February 1, 2020, and prior to December 31, 2020, and have a group number of EC20024005 or EC20024007 or EC20024009 or EC20024011:
    • Pay $10 for up to six, 30-day fills of RYBELSUS® through May 31, 2021. After the patient’s sixth fill, or on June 1, 2021, whichever comes first (the “transition date”), patients without commercial drug coverage for RYBELSUS® will no longer be eligible for this Program. Those patients who do have commercial insurance for RYBELSUS® at the time of the transition date, will then PALA $10 per 30-day supply, $10 per 60-day supply, or $10 per 90-day supply for up to 24 months from the activation date, subject to a maximum savings of $300 per 30-day supply, $600 per 60-day supply, or $900 per 90-day supply. RYBELSUS® 3 mg strength is limited to a 30-day supply only.
  • If you enrolled for your offer on, or after, December 31, 2020, and have a group number other than the ones listed in the first two bullets:
    • Pay as little as ("PALA") $10 per 30-day supply, $10 per 60-day supply, or $10 per 90-day supply for up to 24 months from the activation date, subject to a maximum savings of $300 per 30-day supply, $600 per 60-day supply, or $900 per 90-day supply. Offer available only to commercially insured patients with RYBELSUS® coverage. RYBELSUS® 3 mg strength is limited to a 30-day supply only.

Pharmacist:

When you apply this offer, you are certifying that you have not submitted a claim for reimbursement under any Government Program for this prescription, or where prohibited by law. Participation in this program must comply with all applicable laws and regulations as a pharmacy provider. By participating in this program, you are certifying that you will comply with the eligibility criteria, and terms and conditions described herein. You also certify that you will not seek reimbursement for any benefit received through this offer.

Pharmacist instructions for a patient with an Eligible Third Party:

Submit the claim to the primary Third Party Payer first, then submit the balance due to CHANGE HEALTHCARE as a Secondary Payer COB [coordination of benefits] with patient responsibility amount and a valid Other Coverage Code, (eg, 8). The patient is responsible initially for the PALA amount and the offer pays up to the Savings Benefit. Offer excludes full cash-paying patients. Reimbursement will be received from CHANGE HEALTHCARE. For any questions regarding CHANGE HEALTHCARE online processing, please call the Help Desk at 1–800–433–4893.